Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Bleeding Complications After Contemporary Pharmacoinvasive Therapy for ST Elevation Myocardial Infarction

Abstract

Background: Pharmacoinvasive therapy for the treatment of ST elevation myocardial infarction (STEMI) is a strategy that combines early restoration of coronary flow via pharmacologically induced thrombolysis with subsequent, prompt percutaneous coronary intervention (PCI). Prior studies suggesting a heightened bleeding risk of PCI performed early after fibrinolysis predated contemporary pharmacoinvasive practice including use of femoral closure devices (CD), fibrin specific thrombolytics, lower doses of heparin and stents.

Methods: Consecutive patients were included in this retrospective registry study if they underwent emergent PCI for ST elevation myocardial infarction (STEMI) followed by immediate use of a groin closure device. Between Oct 1, 2002 and Jan 1, 2003, 27 patients were treated with immediate use of CD after post-thrombolytic PCI, performed within 12 hours of thrombolysis (pharmacoinvasive group). 58 patients were treated with immediate use of CD after primary PCI for STEMI. The two groups were compared with respect to the incidence of successful groin closure, bleeding complications, and clinical outcomes. Bleeding events were categorized according to the TIMI criteria. All baseline clinical and treatment variables were compared between the two groups to determine and the association of these variables (including use of thromblytic therapy) with TIMI major and TIMI minor bleeding was determined.

Results: Pharmacoinvasive recanalization with PCI occurred 348 ± 183 minutes after initiation of fibrinolytic therapy. Glycoprotein IIb/IIIa inhibitors were used less frequently in the patients treated with a thrombolytic agent (59% vs. 90%, p < 0.01). Successful immediate hemostasis was obtained with CD in greater than 85% of patients in both groups (89% for pharmacoinvasive group vs. 86% for primary PCI group, p = 0.89). No patient required vascular surgical intervention. TIMI major bleeding and transfusion requirements were less than 5% in both groups. Antecedent thrombolytic therapy was not a predictor of bleeding complications after PCI.

Conclusions: Use of CD as part of a contemporary pharmacoinvasive strategy is associated with a low rate of major bleeding complications.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Dauerman HL, Sobel BE. Synergistic treatment of ST-segmentelevation myocardial infarction with pharmacoinvasive recanalization. J Am Coll Cardiol 2003;42:646–651.

  2. 2.

    Dauerman HL. The early days after ST-segment elevation acute myocardial infarction: Reconsidering the delayed invasive approach. J Am Coll Cardiol 2003;42:420–423.

  3. 3.

    Scheller B, Hennen B, Hammer B, et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003;42:634–641.

  4. 4.

    SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. BMJ 1991;302:555–560.

  5. 5.

    Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group. N Engl J Med 1989;320:618–627.

  6. 6.

    Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999;34:1954–1962.

  7. 7.

    Blankenship JC, Balog C, Sapp SK, et al. Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. Catheter Cardiovasc Interv 2002;57:476–483.

  8. 8.

    Applegate RJ, Grabarczyk MA, Little WC, et al. Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization. J Am Coll Cardiol 2002;40:78–83.

  9. 9.

    Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial–phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1–11.

  10. 10.

    Baim DS, Knopf WD, Hinohara T, et al. Suture-mediated closure of the femoral access site after cardiac catheterization: Results of the suture to ambulate aNd discharge (STAND I and STAND II) trials. Am J Cardiol 2000;85:864–869.

  11. 11.

    Sanborn TA, Gibbs HH, Brinker JA, Knopf WD, Kosinski EJ, Roubin GS. A multicenter randomized trial comparing a percutaneous collagen hemostasis device with conventional manual compression after diagnostic angiography and angioplasty. J Am Coll Cardiol 1993;22:1273–1279.

  12. 12.

    Dauerman HL, Prpic R, Andreou C, Popma JJ. Resolution of coronary thrombus with rescue stenting. Am J Cardiol 2000;85:1244–1247.

  13. 13.

    Dauerman HL, Andreou C, Perras MA, Spinner JS, Lessard D, Weiner BH. Predictors of bleeding complications after rescue coronary interventions. J Thromb Thrombolysis 2000;10:83–88.

  14. 14.

    Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: Results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol 2000;36:1489–1496.

  15. 15.

    Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol 2003;42:7–16.

  16. 16.

    Resnic FS, Blake GJ, Ohno-Machado L, Selwyn AP, Popma JJ, Rogers C. Vascular closure devices and the risk of vascular complications after percutaneous coronary intervention in patients receiving glycoprotein IIb-IIIa inhibitors. Am J Cardiol 2001;88:493–496.

  17. 17.

    Tiefenbrunn AJ, Robinson AK, Kurnik PB, Ludbrook PA, Sobel BE. Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1985;71:110–116.

  18. 18.

    Dangas G, Mehran R, Kokolis S, et al. Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. J Am Coll Cardiol 2001;38:638–641.

  19. 19.

    Dauerman HL, Ryan TJ, Jr., Piper WD, et al. Outcomes of percutaneous coronary intervention among elderly patients in cardiogenic shock: A multicenter, decade-long experience.J Invasive Cardiol 2003;15:380–384.

  20. 20.

    Steg G, Aubry P. Radial access for primary PTCA in patients with acute myocardial infarction and contraindication or impossible femoral access. Cathet Cardiovasc Diagn 1996;39:424–426.

  21. 21.

    Muller DW, Shamir KJ, Ellis SG, Topol EJ. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol 1992;69:63–68.

  22. 22.

    Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957–966.

  23. 23.

    Boccalandro F, Assali A, Fujise K, Smalling RW, Sdringola S. Vascular access site complications with the use of closure devices in patients treated with platelet glycoprotein IIb/IIIa inhibitors during rescue angioplasty. Catheter Cardiovasc Interv 2004;63:284–289.

  24. 24.

    Warren BS, Warren SG, Miller SD. Predictors of complications and learning curve using the Angio-Seal closure device following interventional and diagnostic catheterization. Catheter Cardiovasc Interv 1999;48:162–166.

  25. 25.

    Sesana M, Vaghetti M, Albiero R, et al. Effectiveness and complications of vascular access closure devices after interventional procedures. J Invasive Cardiol 2000;12:395–399.

  26. 26.

    Pracyk JB, Wall TC, Longabaugh JP, et al. A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention. Am J Cardiol 1998;81:970–976.

  27. 27.

    Nasser TK, Mohler ER, III, Wilensky RL, Hathaway DR. Peripheral vascular complications following coronary interventional procedures. Clin Cardiol 1995;18:609–614.

Download references

Author information

Correspondence to Harold L. Dauerman MD.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gutierrez, M.J., Aggarwal, A., Gilbert, K. et al. Bleeding Complications After Contemporary Pharmacoinvasive Therapy for ST Elevation Myocardial Infarction. J Thromb Thrombolysis 18, 187–192 (2004). https://doi.org/10.1007/s11239-005-0344-7

Download citation

Key Words

  • thrombolysis
  • acute myocardial infarction
  • percutaneous coronary intervention
  • pharmacoinvasive therapy